Skip to main content
OpenTrials
Completed

NCT Number: NCT06860230

Philips FAST Evaluation

Evaluation of Philips FAST technology with Nellcor sensors

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Medtronic Clinical Physiology Lab

Denver, Colorado, 80218, United States

About this study

Evaluate saturation accuracy claims for the Philips picoSAT X SpO2 board with FAST algorithm, paired with Nellcor™ sensors in a diverse subject population, over a specified saturation range

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects ≥ 18 and < 51 years of age
  • Subject is willing and able to comply with study procedures and duration
  • Subject is willing to sign an informed consent
  • Subject weighs >40kg
  • Subject is a non-smoker or has not smoked within 36 hours prior to the study
  • Cleared same day health assessment form and health screening

Exclusion criteria

  • Subject is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized)
  • Participants of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study
  • Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure
  • tHb < 10 g/dl as assessed by CO-Oximetry during the procedure
  • MetHb ≥ 2% as assessed by CO-Oximetry during the procedure
  • Subjects with known respiratory conditions such as:
  • uncontrolled / severe asthma
  • flu or influenza type infection
  • pneumonia / bronchitis
  • shortness of breath / respiratory distress
  • unresolved respiratory or lung surgery
  • emphysema, COPD, lung disease
  • recent COVID (last 2 months)
  • Subjects with known heart or cardiovascular conditions such as:
  • hypertension: systolic pressure >140mmHg, or diastolic pressure >90mmHg on 3 consecutive readings
  • previous cardiovascular surgery
  • chest pain (angina)
  • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
  • previous heart attack
  • blocked artery
  • unexplained shortness of breath
  • congestive heart failure (CHF)
  • history of stroke
  • transient ischemic attack
  • carotid artery disease
  • myocardial ischemia
  • myocardial infarction
  • cardiomyopathy
  • implantable active medical device such as pacemaker or automatic defibrillator
  • Self-reported health conditions as identified in the Health Assessment Form
  • diabetes
  • uncontrolled thyroid disease
  • kidney disease / chronic renal impairment
  • history of seizures (except childhood febrile seizures)
  • epilepsy
  • history of unexplained syncope
  • recent history of frequent migraine headaches
  • recent symptomatic head injury, within the last 2 months
  • cancer requiring chemotherapy, radiation, or current treatment
  • subjects with known clotting disorders
  • history of bleeding disorders or personal history of prolonged bleeding from injury
  • history of blood clots
  • hemophilia
  • sickle cell trait or disease
  • current use of blood thinner: prescription or daily use of aspirin
  • subjects with Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • participants with severe allergy to iodine (only applicable if iodine is used)
  • subjects with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin
  • arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site, left or right)
  • history of clinically significant complications from previous arterial cannulation
  • Failure of Allen's test
  • unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits
  • other known health condition, upon disclosure in Health Assessment form at PI's discretion

Treatment and study plan

Philips FAST SpO2 with Nellcor Pulse Oximetry Sensors

Device

Noninvasive pulse oximeter

Primary outcomes

  1. Evaluation of Saturation Accuracy

    Time frame: 2 - 3 hours

    Performance will be determined by calculating the accuracy in terms of root mean square difference (ARMS) comparing the noninvasive oxygen saturation measurement (SpO2) to the arterial oxygen saturation (SaO2) value obtained from a reference blood sample.

Sponsors and collaborators

Lead sponsor

Medtronic - MITG

Industry

Collaborators

  • Philips Medical Systems

Registry information

Official study title

Evaluation of NellcorTM Pulse Oximetry Accuracy With the Philips picoSAT X SpO2 Board With Fourier Artifact Suppression Technology in Adult Volunteers

Acronym: NELFST

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 5, 2025
Registry last updated
Jul 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.